Cargando...
Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
Follicular lymphoma (FL) is the second most common type of non-Hodgkin’s lymphoma. FL is an incurable disease with treatment options ranging from a “watch-and-wait” approach to localized therapy with radiation or systemic therapy with rituximab in combination with chemotherapy regimens. This review...
Gardado en:
| Publicado en: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5411111/ https://ncbi.nlm.nih.gov/pubmed/28479860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S120589 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|